Perspectify News
3 hours ago
Hottest science and technology news from the United States
Provided by AGP
AGP Picks
View all
Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Filter
As featured in:
@ Journalists!
Join
Press releases
Publish your press release
15 hours ago
Royal Moving & Storage Provides Insights on Factors Affecting Long-Distance Moving Costs Across Major U.S. Cities
EIN Presswire
Distance, access conditions, delivery timelines, and regional logistics continue to influence interstate relocation planning LOS ANGELES, CA, UNITED STATES, May 9, 2026 /EINPresswire.com/ -- Royal Moving & Storage reports that long-distance...
9 hours ago
TMB Tax & Financial Services Founder Talibah M. Bayles Selected as Director of the Miles College Women’s Business Center
EIN Presswire
Talibah M. Bayles, Founder of TMB Tax & Financial Services, has been selected as Director of the SBA-funded Miles College Women’s Business Center in Alabama.
May. 8, 2026
U.S. Army Corps of Engineers to begin Ocean City dredging ahead of tourist season
DVIDS - Georgia
BALTIMORE — The U.S. Army Corps of Engineers (USACE), Baltimore District, is scheduled to remove approximately 15,000 cubic yards of dredged material from the Ocean City Inlet beginning Friday, May 8, 2026. The dredge MURDEN will begin dredging...
May. 7, 2026
U.S. Navy Launches Strike on Iranian Oil Tanker
MENAFN
World and Middle East business and financial news, Stocks, Currencies, Market Data, Research, Weather and other data.
May. 8, 2026
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
GlobeNewswire, Inc.
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative Patients treated with VYVGART...
May. 8, 2026
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
GlobeNewswire, Inc.
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that a...
Video Stories
Discover Affinity Group Publishing
Sign up for:
American Tech Today
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.
Explore More
